PortalPublikationenSuccessful intra-class switching among IL-17 antagonists: a ...

Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study

Standard

Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study. / Gasslitter, Irina; Kirsten, Natalia; Augustin, Matthias; Torz, Kaspar; Mrowietz, Ulrich; Eyerich, Kilian; Puig, Lluís; Hoetzenecker, Wolfram; Schütz-Bergmayr, Martina; Weger, Wolfgang; Wolf, Peter; Reider, Norbert; Ratzinger, Gudrun; Papageorgiou, Karolina; Meier, Thomas O; Maul, Julia-Tatjana; Anzengruber, Florian; Navarini, Alexander A.

in: ARCH DERMATOL RES, Jahrgang 311, Nr. 5, 07.2019, S. 421-424.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Gasslitter, I, Kirsten, N, Augustin, M, Torz, K, Mrowietz, U, Eyerich, K, Puig, L, Hoetzenecker, W, Schütz-Bergmayr, M, Weger, W, Wolf, P, Reider, N, Ratzinger, G, Papageorgiou, K, Meier, TO, Maul, J-T, Anzengruber, F & Navarini, AA 2019, 'Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study', ARCH DERMATOL RES, Jg. 311, Nr. 5, S. 421-424. https://doi.org/10.1007/s00403-019-01907-y

APA

Gasslitter, I., Kirsten, N., Augustin, M., Torz, K., Mrowietz, U., Eyerich, K., Puig, L., Hoetzenecker, W., Schütz-Bergmayr, M., Weger, W., Wolf, P., Reider, N., Ratzinger, G., Papageorgiou, K., Meier, T. O., Maul, J-T., Anzengruber, F., & Navarini, A. A. (2019). Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study. ARCH DERMATOL RES, 311(5), 421-424. https://doi.org/10.1007/s00403-019-01907-y

Vancouver

Gasslitter I, Kirsten N, Augustin M, Torz K, Mrowietz U, Eyerich K et al. Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study. ARCH DERMATOL RES. 2019 Jul;311(5):421-424. https://doi.org/10.1007/s00403-019-01907-y

Bibtex

@article{ef1054da77464f658ccc2801be2d63fe,
title = "Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study",
abstract = "IL-17 blockers are among the newer anti-psoriatic treatment options and little is known about the interclass switching. We have thus initiated a multi-center, multi-national, retrospective study to assess the treatment response of patients who were switched from one IL-17 blocker to another. Analysis consisted of data from patients with moderate-to-severe psoriasis who did not respond satisfactorily to one of the available IL-17 blockers (secukinumab, ixekizumab, brodalumab) and were subsequently switched to another drug of this class. After 12 weeks of treatment, patients' PASIs were evaluated. Treatment success was defined as reaching PASI 75 after 12 weeks. Topical treatment was allowed and used in all patients. 26 patients were included (13 male, 13 female) and 29 switches were evaluated. Overall, 29 switches in 21 patients were evaluated. 18 patients changed their therapy from secukinumab to ixekizumab, or in 7 cases to brodalumab. Brodalumab was used in 3 cases after failure of treatment with ixekizumab. Only in one case, non-response of brodalumab resulted in a therapy switch to secukinumab. In 15 (52%) cases, PASI 75 was reached. In 6 (20%) patients, the switch led to a PASI 50 response. No success of treatment was seen among 8 (28%) participants. When patients fail to respond or do not tolerate an IL-17 blocker, switching to another anti-IL-17A/RA is a promising viable option. Larger studies are needed to confirm our results.",
author = "Irina Gasslitter and Natalia Kirsten and Matthias Augustin and Kaspar Torz and Ulrich Mrowietz and Kilian Eyerich and Llu{\'i}s Puig and Wolfram Hoetzenecker and Martina Sch{\"u}tz-Bergmayr and Wolfgang Weger and Peter Wolf and Norbert Reider and Gudrun Ratzinger and Karolina Papageorgiou and Meier, {Thomas O} and Julia-Tatjana Maul and Florian Anzengruber and Navarini, {Alexander A}",
year = "2019",
month = jul,
doi = "10.1007/s00403-019-01907-y",
language = "English",
volume = "311",
pages = "421--424",
journal = "ARCH DERMATOL RES",
issn = "0340-3696",
publisher = "Springer",
number = "5",

}

RIS

TY - JOUR

T1 - Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study

AU - Gasslitter, Irina

AU - Kirsten, Natalia

AU - Augustin, Matthias

AU - Torz, Kaspar

AU - Mrowietz, Ulrich

AU - Eyerich, Kilian

AU - Puig, Lluís

AU - Hoetzenecker, Wolfram

AU - Schütz-Bergmayr, Martina

AU - Weger, Wolfgang

AU - Wolf, Peter

AU - Reider, Norbert

AU - Ratzinger, Gudrun

AU - Papageorgiou, Karolina

AU - Meier, Thomas O

AU - Maul, Julia-Tatjana

AU - Anzengruber, Florian

AU - Navarini, Alexander A

PY - 2019/7

Y1 - 2019/7

N2 - IL-17 blockers are among the newer anti-psoriatic treatment options and little is known about the interclass switching. We have thus initiated a multi-center, multi-national, retrospective study to assess the treatment response of patients who were switched from one IL-17 blocker to another. Analysis consisted of data from patients with moderate-to-severe psoriasis who did not respond satisfactorily to one of the available IL-17 blockers (secukinumab, ixekizumab, brodalumab) and were subsequently switched to another drug of this class. After 12 weeks of treatment, patients' PASIs were evaluated. Treatment success was defined as reaching PASI 75 after 12 weeks. Topical treatment was allowed and used in all patients. 26 patients were included (13 male, 13 female) and 29 switches were evaluated. Overall, 29 switches in 21 patients were evaluated. 18 patients changed their therapy from secukinumab to ixekizumab, or in 7 cases to brodalumab. Brodalumab was used in 3 cases after failure of treatment with ixekizumab. Only in one case, non-response of brodalumab resulted in a therapy switch to secukinumab. In 15 (52%) cases, PASI 75 was reached. In 6 (20%) patients, the switch led to a PASI 50 response. No success of treatment was seen among 8 (28%) participants. When patients fail to respond or do not tolerate an IL-17 blocker, switching to another anti-IL-17A/RA is a promising viable option. Larger studies are needed to confirm our results.

AB - IL-17 blockers are among the newer anti-psoriatic treatment options and little is known about the interclass switching. We have thus initiated a multi-center, multi-national, retrospective study to assess the treatment response of patients who were switched from one IL-17 blocker to another. Analysis consisted of data from patients with moderate-to-severe psoriasis who did not respond satisfactorily to one of the available IL-17 blockers (secukinumab, ixekizumab, brodalumab) and were subsequently switched to another drug of this class. After 12 weeks of treatment, patients' PASIs were evaluated. Treatment success was defined as reaching PASI 75 after 12 weeks. Topical treatment was allowed and used in all patients. 26 patients were included (13 male, 13 female) and 29 switches were evaluated. Overall, 29 switches in 21 patients were evaluated. 18 patients changed their therapy from secukinumab to ixekizumab, or in 7 cases to brodalumab. Brodalumab was used in 3 cases after failure of treatment with ixekizumab. Only in one case, non-response of brodalumab resulted in a therapy switch to secukinumab. In 15 (52%) cases, PASI 75 was reached. In 6 (20%) patients, the switch led to a PASI 50 response. No success of treatment was seen among 8 (28%) participants. When patients fail to respond or do not tolerate an IL-17 blocker, switching to another anti-IL-17A/RA is a promising viable option. Larger studies are needed to confirm our results.

U2 - 10.1007/s00403-019-01907-y

DO - 10.1007/s00403-019-01907-y

M3 - SCORING: Journal article

C2 - 30879102

VL - 311

SP - 421

EP - 424

JO - ARCH DERMATOL RES

JF - ARCH DERMATOL RES

SN - 0340-3696

IS - 5

ER -